At RetinAI, we are more than a collection of skilled individuals. We are a unified team, working together for a greater goal: enabling the right decisions sooner in healthcare, particularly in Ophthalmology!

As part of this journey, our research team is dedicated to elevating your research & data analysis with the efficiency our AI technology enables. Whether you are focused on clinical trials, drug development or academia, we are here to offer technology solutions that are tailored to your needs.   

Curious about what it’s like to collaborate with us and the benefits it brings? Let’s explore how RetinAI can deliver customized solutions to elevate your work. 
5 minutes read

‍

‍

How is it to work with RetinAI?

When we commit to a partnership, we make it our priority to meet every one of your needs. How do we do it? Through a simple 3-step-process:

‍

1. Planning
   ‍We start creating a work plan together to address your key questions and expectations. We take the time to understand your pipeline, its challenges and opportunities, and then apply our expertise to find the best way to answer your research questions. We use quantitative imaging biomarkers from OCT, to help support your research objectives.
   ‍
2. Analysis
   ‍Our research team is well-versed in applying statistical methods that will be aligned with the needs of the evaluation and can include descriptive as well as inferential statistics. The appropriate metrics to evaluate each objective are discussed with one of our data scientists, following state-of-the-art analysis.
   ‍
3. Report
   A complete statistical report is compiled for you, explaining the results obtained from the data analysis, usually a deep dive into the subgroup analyses depending on the research needs, and a conclusion about the clinical relevance of the findings.

How can we help you? 
‍

Our experience in data analysis is broad: from pilot studies to complex clinical trials and real-world evidence evaluations, where we can help you understand your data with AI-driven technology complemented with human research expertise.

‍

Our in-depth analysis of data shows a variety of applications that will help our clients plan and be better prepared for upcoming projects. By leveraging real-time access to data, we aim to make the research process more adaptable to emerging insights that will help tune future clinical studies. Our ultimate goal is to streamline clinical trials, by improving their efficiency and enhancing the probability of success.
‍

‍

As we recently unveiled our latest OCT Segmentation model, you will find below some examples using it, and how it benefited our clients.

‍

Clinical Trial Data

Leverage data from past or ongoing clinical trials with capabilities to standardize data in a single ecosystem. Our OCT Segmentation model can help you extract robust insights about your clinical trial results (Figure 1):

• Gain an in-depth understanding of the patient‘s response to treatment by characterizing disease progression and outcomes over time
• Divide the population into subgroups to assess biomarker-based profiles and develop predictive analytics to save time and effort in future trials by refining your trial endpoints and optimising the inclusion and exclusion criteria
  
  ‍

‍

Discovery provides an opportunity to efficiently collect, share and interpret images with advanced AI tools in a timely manner as the trial proceeds. Dr. René Ruckert, Chief Operating Officer @ Isarna Therapeutics

‍

I’ve had the privilege of partnering with the team at RetinAI on several projects. The team’s responsiveness, innovation, and collaborative approach have been instrumental in helping us obtain new insights and has led to our decision to sustain our partnership across multiple projects. Lori Huang, PharmD, MBA, Vice President, Clinical Affairs @ ONL Therapeutics, Inc.

‍

‍

Introducing Discovery UNITY 

Discovery UNITY is our advanced multimodality platform that accelerates research and development in the pharma and life sciences sectors.

It supports a wide range of imaging formats and integrates AI to analyze clinical data at scale.
‍
By organizing and analyzing data into a single ecosystem, Discovery UNITY enables efficient and collaborative research, reducing the time and costs associated with clinical trials.

‍

‍
With secure, cloud-based access, researchers can collaborate globally, gaining insights that drive precision medicine forward. 

‍

‍

‍

‍

‍

‍

Real World Evidence

We collaborate with Retina Consultants of America (RCA) to build the most extensive and comprehensive real-world evidence (RWE) database in ophthalmology. RWE provides valuable insights into using different therapies in everyday practice (e.g., healthcare outcomes, medication adherence, treatment protocol efficiency), which may differ from results observed in controlled, clinical trials.

• Our OCT Segmentation model can process and interrogate a large volume of data, improving the understanding of real-world data, corroborating previous data assumptions or helping generate and validate new hypotheses. Our analysis will provide you with a better understanding of drug efficacy and safety, the natural history of the disease, and the target population in the real world.
  ‍
• Data analysis covers the distribution of layer thicknesses and fluid volume across a population; the progression of layer and fluid measurements over time; and the attenuation/loss of retinal layers (depletion maps) and atrophic areas (Figure 2), among others. This analysis will be backed up by a comprehensive statistical analysis plan.

‍

‍

We’ve established the largest group of top-ranked retinal care and research practices in the U.S. and through this network and this collaboration with RetinAI, we want to unlock a deeper level of understanding of retinal diseases. We are proud to partner with RetinAI in our mutual fight against blindness. Dr. David M. Brown, Chairman of RCA’s Medical Leadership Board

‍

‍

A platform powered by scientific contributions

‍

A stepping stone into understanding Geographic Atrophy

Since the approval of the first drug targeting GA in early 2023, the interest in better understanding GA has grown exponentially. Moreover, many clinical trials are ongoing, investigating different compounds' potential efficacy and safety.
‍

At RetinAI, one of our goals is to streamline GA assessment to improve patients' care, providing automated tools that aid healthcare professionals in deepening the analysis and overcoming the current limitations.

‍

This was our focus at ARVO 2024, where we presented two main posters on GA. Our first ARVO presentation aimed to understand the relationship between Fundus Autofluorescence (FAF) lesions and OCT findings, in collaboration with Prof. Dr. Dr. Marion Munk and Dr. Irmela Mantel. Our results showed strong correlations between FAF lesions and the loss of RPE and photoreceptor layers in OCT, supporting that OCT can be used in GA assessment for clinical trials and clinical practice.

‍

For our second presentation, we investigated the retinal layer thickness surrounding RORA lesions using OCT A-scans, in collaboration with Dr. Robyn Guymer and Dr. Zhichao Wu (Centre for Eye Research Australia). We showed a distinct spatial distribution of photoreceptor, RPE, and CC+CS thickness loss outside the lesion boundaries. This behavior might be related to further RORA lesion spreading and may help identify early biomarkers for disease progression. 

‍

‍

Exploring a large spectrum of retinal disorders

RetinAI’s Discovery is not just a tool, but a comprehensive platform that can be tailored for studying different retinal diseases.

Our team has collaborated with several clinicians, research groups, and Pharma companies to better understand the complexities of other retinal diseases such as neovascular AMD, Diabetic Retinopathy, Diabetic Macular Edema, Central Serous Chorioretinopathy, as well as rare retinal disorders such as multifocal choroiditis (MFC) and punctate inner choroidopathy (PIC).   

Visit our website to check out our updated list of scientific publications as well as specific use cases of RetinAI's Discovery platform.

‍

This article was written by Romina Lasagni Vitar, PhD and Joseph Blair, PhD